Robert Ćhilton

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom et al. · The Lancet · 2017 · 855 citations · Full text

Thrombosis, Cardiovascular Disease, Stroke +13

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch et al. · The Lancet · 2017 · 749 citations · Full text

Thrombosis, Cardiovascular Disease, Atherosclerosis +12

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Robert Ćhilton, I. Tikkanen, Christopher P. Cannon et al. · Diabetes Obesity and Metabolism · 2015 · 494 citations · Full text

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

Muhammad Abdul‐Ghani, Stefano Del Prato, Robert Ćhilton et al. · Diabetes Care · 2016 · 297 citations · Full text

Hypertension, Heart Failure, Cardiovascular Pharmacology +20

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

Ian J. Neeland, Darren K. McGuire, Robert Ćhilton et al. · Diabetes and Vascular Disease Research · 2015 · 160 citations · Full text